Abstract
Introduction

Localized myxedema is an infrequent manifestation of Graves' disease. It is characterized by localized thickening of the skin (1-3). Myxedema is commonly localized in the pretibial area. Therefore, it is often referred to as pretibial myxedema (PTM). PTM is a sign of Graves' disease. TSH receptor antibodies (TRAb) cause Graves' hyperthyroidism (4). TRAb has been reported to be associated with PTM (5-8), and may play some role in the development of PTM. TRAb has been measured as thyroid stimulating antibody (TSAb) or TSH-binding inhibitory immunoglobulin (TBII)
. In the present report, we describe a patient, in whom PTM developed after radioisotope 131 I treatment for Graves' hyperthyroidism. TRAb also increased after 131 (2, 3, (10) (11) (12) . Kriss et al (10) and Fatourechi et al (2, 3) have reported moderate benefits of topical corticosteroid therapy. A long-term experience with thyroid dermopathy has been reported by only one group (2, 3, 13 A 53-year-old Japanese man visited our department with rapidly developing localized pretibial myxedema (PTM) and was admitted to our hospital (Fig. 1A, Fig. 3 c i a n b l u e s t a i n i n g ( × 4 0 ) . Mu c i n  s t a i n i n g d e mo n s t r a t e d a b u n d a n t d i f f u s e mu c i n wi t h i n t h e d e r ma l f e n e s t r a t i o n s a s l a r g e a mo u n t s o (Cases 1 and 2) . In these two patients, the T a b l e 1 . S i x P a t i e n t s wi t h L o c a l i z e d P r e t i b i a (7, 8) . Daumerie et al (8) reported that TSH receptor was present in the pretibial area in the Graves' patients with PTM, but absent in controls without thyroid diseases. Heufelder et al (14) proposed the TSHreceptor as the common target auto-antigen in GD and PTM. Daumerie et al (8) 
I treatment in this patient. Various treatment modalities have been employed, including topical and systemic corticosteroids, compression dressings, and local injections
F i g u r e 1 . P r e t i b i a l my x e d e ma ( Ca s e 1 ) . A. P r e t i b i a l my x e d e ma ( P T M) o n a d mi s s i o n ( 0 t i me i n F i g . 3 ) . T h e a r r o w i n d i c a t e s t h e ma r g i n o f P T M. B . S c h e ma t i c r e p r e s e n t a t i o n f o r A. P T M-a n d p i g me n t a t i o n -a r e a s a r e s h o wn . T h e a r r o w i n d i c a t e s t h e ma r g i n o f P T M. C. P T M wa s e f f e c t i v e l y t r e a t e d wi t h s t e r o i d o i n t me n t a p p l i c a t i o n wi t h s e a l i n g c o v e r ( s t e r o i d o c c l u s i v e d r e s s i n g t e c h n i q u e
. Hi s t o l o g y o f p r e t i b i a l my x e d e ma ( P T M) ( Ca s e 1 ) . Hi s t o l o g i c a l e x a mi n a t i o n r e v e a l e d f r a y i n g o f c o n n e c t i v e t i s s u e f i b e r s , a n d d e p o s i t s o f c o l l o i d a l i r o n ( A) -a n d Al c i a n b l u e ( B ) -s t a i n e d mu c i n o u s ma t e r i a l s , d e mo n s t r a t i n g h i s t o p a t h o l o g i c f e a t u r e s o f P T M. A. B l u e s t a i n i n g o f mu c i n wi t h c o l l o i d a l i r o n s t a i n i n g ( × 1 0 0 ) . B . Mu c i n o u s ma t e r i a l s wi t h Al
I t r e a tme n t , T S Ab ( t h y r o i d s t i mu l a t i n g a n t i b o d y ) t i t e r s we
I t r e a t me n t f o r Gr a v e s ' h y p e r t h y r o i d i s m, t h e T S Ab i n c r e a s e d t o 2 , 5 0 0 % a n d T B I I i n c r e a s e d t o 8 5 %. P T M wa s s u c c e s s f u l l y t r e a t e d wi t h t o p i c a l s t e r o i d ( t r i a mc i n o l o n e a c e t o n i d e ) o i n t me n t a p p l i c at i o n wi t h s e a l i n g c o v e r ( s t e r o i d o c c l u s i v e d r e s s i n g t e c h n i q u e : s t e r o i d ODT ) . Wi t h s t e r o i d ODT , P T M s u b s i d e d . P T M a pp e a r e d wi t h t h e i n c r e a s e s o f T RAb ( T S H r e c e p t o r a n t i b o d y ) ( T S Ab a n d T B I I ) , a n d d i s a p p e a r e d wi t h s t e r o i d ODT , e v e n i n t h e p r e s e n c e o f p o s i t i v e T RAb .
l My x e d e ma ( P T M) a n d Gr a v e s ' Hy p e r t h y r o i d i s m ( GD) ; P T M T r e a t me n t wi t h T o p i c a l S t e r o i d Oi n t me n t Ap p l i c a t i o n wi t h S e a l i n g Co v e r ( s t e r o i d Oc c l u s i v e Dr e s s i n g T e c h n i q u e : S t e r o i d ODT )
